ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Adalimumab and biosimilars"

  • Abstract Number: 2446 • 2017 ACR/ARHP Annual Meeting

    Minimal and Comparable Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Who Continued SB5 or Reference Adalimumab and Who Switched to SB5

    Michael Weinblatt1, Asta Baranauskaite2, Jeehoon Ghil3, Soo Yeon Cheong3 and Evelyn Hong3, 1Brigham and Women’s Hospital, Boston, MA, 2Lithuanian University of Health Sciences, Kaunas, Lithuania, 3Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

    Background/Purpose : SB5 is a biologic agent developed as a biosimilar of the reference adalimumab (ADL). One year results including radiographic progression from the phase…
  • Abstract Number: 2757 • 2015 ACR/ARHP Annual Meeting

    Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis

    Alan K. Matsumoto1, Karel Pavelka2, Warren Rizzo3, Ramesh Gupta4, William Shergy5, Pawel Heycaj6, Nan Zhang7 and Primal P. Kaur8, 1Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, 2Charles University, Prague, Czech Republic, 3Advanced Arthritis Care & Research, Scottsdale, AZ, 4Private Practice, Rheumatology, Memphis, TN, 5RANA Clinical Research Center, Huntsville, AL, 6Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, 7Biosimilars, Amgen, Inc., Thousand Oaks, CA, 8Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons…
  • Abstract Number: 1503 • 2014 ACR/ARHP Annual Meeting

    Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501

    Teresa Born1, Jyoti Velayudhan2, Yuh-fung Chen3, Heather Thomas4, Christina Pastula2, Gwen Maher3 and Ryan Brown4, 1Biosimilars Process Development, Amgen, Seattle, WA, 2Functional Biocharacterization, Amgen, Seattle, WA, 3Functional Biocharacterization, Amgen, Thousand Oaks, CA, 4Inflammation Research, Amgen, Seattle, WA

    Background/Purpose: ABP 501 is being developed as a biosimilar to adalimumab, a recombinant monoclonal antibody that binds tumor necrosis factor alpha (TNF) thus inhibiting engagement…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences